Maureen is a co-founder and CEO of Hexagon Bio. Previously she was the director of the Genomes to Natural Products program at the Stanford Technology Genome Center, where she led technology development for discovery of drug-like metabolites using bioinformatics and synthetic biology. Maureen’s interdisciplinary background spans biology, genomics, and computer science, representing the interdisciplinary nature of Hexagon as a company.

Maureen has a Ph.D. in Biomedical Informatics from Stanford University, and a B.A. in Biology from the University of Notre Dame.

Brian Naughton is a co-founder and Chief Technology Officer at Hexagon Bio. He was previously VP and founding scientist at 23andMe, where he worked on algorithm development for large-scale human genetics data. Brian’s research interests are in the genetics of disease and the analysis of biological data.

Brian has a Ph.D. in Biomedical Informatics from Stanford University, and a B.A. in Human Genetics from Trinity College, Dublin.

Tara is Chief Scientific Officer at Hexagon Bio. She previously served as Hexagon’s Senior Vice President, Research. Prior to joining Hexagon, Tara was an Executive Director of Oncology Research at Amgen where she led small molecule and large molecule programs in Oncology, Immuno-Oncology, Inflammation and Hematology. Notable accomplishments include initiation of Amgen’s KRAS G12C-targeting effort which resulted in the first approved KRAS targeting molecule, LUMAKRAS™ (sotorasib), and leadership of Amgen’s bispecific T cell engager platform, which resulted in several current clinical candidates.

Tara received her Ph.D. in Biochemistry from the California Institute of Technology and was a Damon Runyon Postdoctoral Fellow at the University of California, San Diego.

Victor is Senior Vice President, Drug Discovery at Hexagon Bio. He obtained a B.S. degree in Chemistry from the University of Utah in 1997 and a Ph.D. degree in Organic Chemistry from Harvard University in 2003. He joined the Medicinal Chemistry department at Amgen in 2003 and contributed to numerous small molecule drug discovery programs including Tie-2 kinase, Aurora kinase (AMG 900), S1P1 (AMG 369), PI3K (AMG 511), Pim kinase, and RORT. He led the KRASG12C research team from project inception to the identification and characterization of AMG 510, which went on to become Amgen’s first in class KRASG12C inhibitor LUMAKRAS™ (sotorasib), approved in the United States in 2021 for the treatment of KRASG12C-positive non-small cell lung cancer. In 2020 he joined Oncovalent Therapeutics as Vice President, Chemistry, where he directed drug discovery efforts and platform technology focused on identifying and advancing covalent inhibitors for oncology indications.

Natacha is Vice President, Biology at Hexagon Bio. Natacha brings 15 years of R&D experience on platform technologies across multiple therapeutic areas including oncology, neurological, and inflammatory disorders. Prior to joining Hexagon, Natacha oversaw discovery and IND-stage programs for biologics and small molecules at Ashvattha, Catalyst Biosciences, and Omniox where she contributed to the expansion of companies’ preclinical portfolio and advancement of candidates from target identification to IND. Natacha holds a PhD in Molecular Biology from Paris-Sud University and was a postdoctoral fellow at the Gladstone Institute of Neurological Disease, University of California San Fransisco.

Andy is Vice President, Engineering at Hexagon Bio. Previously he was the Director of Engineering at Palantir Technologies, where he built out the engineering team and oversaw the development of Palantir Metropolis, a quantitative analytics platform. Andy also serves as an advisor to technology startups building their software engineering teams.

Andy studied computer science and mathematics at Stanford University.

Colin is a co-founder and Vice President, Synthetic Biology at Hexagon Bio, where he leads a cross-functional team of fungal geneticists, molecular biologists and engineers to discover therapeutically-relevant secondary metabolites. Previously, he led synthetic biology efforts for natural product discovery at the Stanford Genome Technology Center. Colin’s research interests lie in the discovery of new medicines using the tools of synthetic and molecular biology.

Colin holds a B.Sc. in Chemistry from McGill University, a Ph.D. in Chemistry from Stanford University, and completed postdoctoral training at the Stanford University School of Medicine.